Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 9/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 8/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | CX3CR1 | P49238 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | ESR1 | P03372 | 1/20 | 0.84 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.84 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.84 |
| ▸ | HRH2 | P25021 | 1/20 | 0.84 |
| ▸ | HTR2A | P28223 | 1/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolterodine SCHEMBL6472968 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL2403972 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL110955 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL467372 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL36881 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL1560185 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL29873356 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL6024199 | 0.98 | CHRM3 (0.96) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL6024194 | 0.98 | CHRM3 (0.96) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL1989702 | 0.93 | CHRM3 (0.88) | CHRM3ADRB2CHRM2CHRM1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044001-B1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-N-ALKYL-3-PHENYLPROPYLAMINES | LEK PHARMACEUTICALS (SI) | 2016-11-23 | — | — | EP | claimed |
| EP-1927585-B1 | METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES | INTERQUIM SA (ES) | 2016-07-27 | — | — | EP | claimed |
| EP-1838659-B1 | PROCESS FOR PREPARATION OF N,N-DIISOPROPYL-3-(2-HYDROXY-5-METHYLPHENYL)-3-PHENYLPROPYLAMINE | LEK PHARMACEUTICALS (SI) | 2015-07-15 | — | — | EP | claimed |
| US-8193391-B2 | Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-N-alkyl-3-phenylpropylamines | LEK PHARMACEUTICALS, D.D. (SI) | 2012-06-05 | — | — | US | claimed |
| US-20100234473-A1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-N-ALKYL-3-PHENYLPROPYLAMINES | LEK PHARMACEUTICALS D.D. (SI) | 2010-09-16 | — | — | US | claimed |
| EP-2044001-A1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-N-ALKYL-3-PHENYLPROPYLAMINES | Lek Pharmaceuticals D.D. (SI) | 2009-04-08 | — | — | EP | claimed |
| US-20080045602-A1 | Process for Preparation of 3-(2-Hydroxy-5Methylphenyl)-N, N-Disopropyl-3-Phenylpropylamine | LEK PHARMACEUTICALS, D.D. (SI) | 2008-02-21 | — | — | US | claimed |
| WO-2007147547-A1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-N-ALKYL-3-PHENYLPROPYLAMINES | LEK PHARMACEUTICALS D.D. (SI) | 2007-12-27 | — | — | WO | claimed |
| EP-1838659-A1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-METHYLPHENYL)-N,N-DIISOPROPYL-3PHENYLPROPYLAMINE | LEK Pharmaceuticals D.D. (SI) | 2007-10-03 | — | — | EP | claimed |
| WO-2006066931-A1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-METHYLPHENYL)-N,N-DIISOPROPYL-3PHENYLPROPYLAMINE | LEK PHARMACEUTICALS D.D. (SI) | 2006-06-29 | — | — | WO | claimed |
| EP-2044001-B1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-N-ALKYL-3-PHENYLPROPYLAMINES | LEK PHARMACEUTICALS (SI) | 2016-11-23 | — | — | EP | disclosed |
| EP-1927585-B1 | METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES | INTERQUIM SA (ES) | 2016-07-27 | — | — | EP | disclosed |
| EP-1838659-B1 | PROCESS FOR PREPARATION OF N,N-DIISOPROPYL-3-(2-HYDROXY-5-METHYLPHENYL)-3-PHENYLPROPYLAMINE | LEK PHARMACEUTICALS (SI) | 2015-07-15 | — | — | EP | disclosed |
| US-8193391-B2 | Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-N-alkyl-3-phenylpropylamines | LEK PHARMACEUTICALS, D.D. (SI) | 2012-06-05 | — | — | US | disclosed |
| US-20100234473-A1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-N-ALKYL-3-PHENYLPROPYLAMINES | LEK PHARMACEUTICALS D.D. (SI) | 2010-09-16 | — | — | US | disclosed |
| US-5382600-A | 3,3-diphenylpropylamines and pharmaceutical compositions thereof | PHARMACIA AKTIEBOLAG (SE) | 1995-01-17 | — | — | US | disclosed |
| EP-0325571-B1 | NEW AMINES, THEIR USE AND PREPARATION | Kabi Pharmacia AB (SE) | 1991-08-07 | — | — | EP | disclosed |
| EP-0354234-A1 | NEW AMINES, THEIR USE AND PREPARATION | KabiVitrum AB (SE) | 1990-02-14 | — | — | EP | disclosed |
| WO-1989006644-A1 | NEW AMINES, THEIR USE AND PREPARATION | KABIVITRUM AB (SE) | 1989-07-27 | — | — | WO | disclosed |
| EP-0325571-A1 | New amines, their use and preparation | Kabi Pharmacia AB (SE) | 1989-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234473-A1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-N-ALKYL-3-PHENYLPROPYLAMINES | PAH, ALK, ALKBH3 | CHRM3 1118/4885CHRM2 1618/4885ADRB2 112/4885 |
| US-20080045602-A1 | Process for Preparation of 3-(2-Hydroxy-5Methylphenyl)-N, N-Disopropyl-3-Phenylpropylamine | SLC6A3, PNMT, PIR | CHRM3 988/4885CHRM2 1306/4885ADRB2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.